Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
292.01 USD | -1.79% |
|
-1.19% | -17.24% |
07-14 | United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says | MT |
06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
---|---|---|---|---|
Average | ||||
Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- UTHR Stock
- Consensus United Therapeutics Corporation
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition